Answers are grounded in this paper and cite their sources.
Introduction Meningiomas are hormonally sensitive tumors that occur disproportionately among women with breast cancer. We compared the risk of incident meningioma among patients initiating aromatase inhibitors (AIs) versus tamoxifen. Methods Using the TriNetX Global Collaborative Network (181 healthcare organizations), we identified adults with breast cancer recorded during 2010–2015 who initiated anastrozole, letrozole, or exemestane versus tamoxifen, without exposure to the alternate endocrine therapy class. Cohorts were matched 1:1 on 27 covariates. Incident meningioma was assessed at 1, 2, and 3 years using risk estimates and Cox proportional hazards models. Results After matching, 23,204 patients were included per cohort; 23,110 AI users and 23,114 tamoxifen users without prior meningioma were included in the outcome analyses. Meningioma risk was higher with AIs at 1 year (1.51 vs 0.82 per 1,000; HR 1.846, 95% CI 1.056–3.227), 2 years (2.64 vs 1.56; HR 1.705, 95% CI 1.129–2.574), and 3 years (3.29 vs 2.29; HR 1.449, 95% CI 1.021–2.058). Absolute risk differences were 0.69, 1.08, and 1.00 per 1,000, respectively. Conclusion AI initiation was associated with a modestly higher but progressively attenuating relative risk of meningioma than tamoxifen, with a small absolute excess. These findings should not alter endocrine therapy selection but may inform evaluation of new dural-based lesions in AI users.
No takes yet. Share an insight, caveat, or question.
Wijaya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: